Resumen de: US20260248866A1
0000 An object of the present disclosure is to provide (i) a novel bacteriophage having lytic activity against a Salmonella species such as S. enteritidis or a lytic agent including the same, (ii) a bacteriophage having a broad host range against Salmonella species or a lytic agent including the same, (iii) a host-specific bacteriophage or an effective lytic agent for a Salmonella species including the same, or (iv) a bacteriophage or a lytic agent including the same, capable of effectively controlling S. typhimurium, particularly S. typhimurium having multidrug resistance. The present disclosure provides bacteriophages having specific genomic DNA sequences, lytic agents for Salmonella species including the same, and compositions including the same.
Resumen de: US20260248139A1
A novel bacteriophage having bacteriolytic activity against bacteria of the genus Salmonella, such as S. Enteritidis, and a bacteriolytic agent consisting of the same are provided. The bacteriophage and the bacteriolytic agent including the bacteriophage have a wide host range for bacteria of the genus Salmonella. A host-specific bacteriophage and an effective Salmonella bacteriolytic agent consisting of the same are provided. A bacteriophage capable of effectively controlling S. Typhimurium, and in particular, multidrug-resistant S. Typhimurium, and a bacteriolytic agent consisting of the same are also provided. A bacteriophage having a specific genomic DNA sequence; a Salmonella bacteriolytic agent consisting of the bacteriophage; and a composition comprising the same are provided.
Resumen de: US20260248865A1
0000 A bacteriophage having a wide host range for bacteria of the genus Salmonella is provided. The bacteriophage has bacteriolytic activity against bacteria of the genus Salmonella. The bacteriophage has a genomic DNA sequence comprising a gene encoding a tail tip protein consisting of a specific amino acid sequence. Methods of using the bacteriophage are also provided.
Resumen de: CN122629000A
The invention discloses a strain of Escherichia coli bacteriophage capable of realizing cross-species lysis and application thereof, and belongs to the technical field of bacteriophages. The Escherichia coli bacteriophage vBE.coli PSD29 provided by the invention is preserved in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CGMCC No.47023. Experimental results show that the Escherichia coli bacteriophage vBE.coli PSD29 can split 11 strains of Escherichia coli and 2 strains of salmonella from different livestock sources, the splitting quantity is large, the Escherichia coli bacteriophage vBE.coli PSD29 can keep activity in the environment with the temperature of 4-65 DEG C and the pH value of 3-12, and a genome does not contain genes for coding virulence or drug resistance. The broad-spectrum bacteriophage which is wide in host spectrum, high in splitting power, stable in character and free of potential safety risks is provided for prevention and control of escherichia coli and salmonella in livestock breeding production.
Resumen de: CN122629198A
0001 本发明适用于生物医学诊断技术领域,提供了一种早产儿视网膜病变的肠道菌群标志物组合及其应用,其中,该肠道菌群标志物组合包括产气克雷伯菌和/或丁酸梭菌作为检测靶标。本发明首次在种水平上鉴定出与早产儿视网膜病变风险相关的特异性肠道菌群标志物;其中,肠道菌群中的产气克雷伯菌的丰度与早产儿视网膜病变的风险呈正相关,可作为早产儿视网膜病变的风险预警标志物;肠道菌群中的丁酸梭菌的丰度与早产儿视网膜病变的风险呈负相关,可作为早产儿视网膜病变的保护性标志物;本发明为早产儿视网膜病变的早期预警、风险评估及预后判断提供了全新的无创检测靶点。
Resumen de: CN122629066A
本发明公开了与大肠杆菌特异结合的适配体、生物传感器、试剂盒及用途,属于生物技术与体外诊断技术领域。该适配体包括如SEQ ID NO.1所示的核心序列;其中含有如SEQ ID NO.3所示的核心结合基序,完整序列如SEQ ID NO.2所示。本发明基于活体全菌SELEX技术筛选的适配体对大肠杆菌的亲和力高,特异性强,对复杂样本中的大肠杆菌的捕获效率显著提升。
Resumen de: CN122628211A
The invention belongs to the technical field of biological medicines, and discloses a recombinant protein subunit vaccine constructed by combining salmonella flagellin and a porcine epidemic diarrhea COE region. The invention specifically discloses a fusion protein, the fusion protein comprises a salmonella flagellin FliCL3A mutant and a PEDV (Porcine Epidemic Diarrhea Virus) structural protein, and the PEDV structural protein is connected to the C end of the salmonella flagellin FliCL3A mutant. A subunit vaccine obtained after emulsification of the fusion protein and an adjuvant provided by the invention can effectively prevent PEDV of a G2b subfamily, start a downstream immune response and induce an organism to generate a series of immune responses, so that a mucosal immune system of the organism generates a large number of PEDV specific antibodies to resist invasion of external pathogens, and a specific immune protection effect is achieved.
Resumen de: CN122612721A
0001 本发明涉及生物传感与微流控领域,具体公开了一种集成微流控的小型化电化学生物传感器芯片及其制备方法,包括微流控芯片主体和集成于其内的电化学生物传感器,微流控芯片主体内部设有微流控通道结构,电化学生物传感器包括基底及设置于基底上的工作电极、对电极和参比电极,微流控通道结构与工作电极的表面流体连通。本发明通过将微流控通道与三电极体系在微小面积内一体化集成,并对芯片的整体尺寸、基底厚度及重量进行协同优化,在保证流体密封与键合强度的前提下实现了芯片的显著小型化和轻量化,使其能够灵活适配无人平台载荷,满足移动化、现场化的快速生物侦检需求。
Resumen de: CN122612907A
0001 本发明公开一种C‑反应蛋白功能化广谱病原体捕获磁珠的制备及其在细菌‑病毒共感染免疫层析检测中的应用,基于CRP的复合标记物(CRP‑MDQD)通过逐层自组装策略在Fe<3>O<4>表面连续包覆两层致密的CdSe/ZnS‑COOH量子点构建而成,并公开了其在LFIA中同步富集检测铜绿假单胞菌和SARS‑CoV‑2 NP的应用价值。CRP‑MDQD LFIA平台实现了铜绿假单胞菌与SARS‑CoV‑2 NP的无抗体同步富集检测。该生物传感器具有卓越的基质耐受性,其"抗体非依赖"设计突破了传统多重检测的固有局限,为资源有限环境下病毒‑细菌混合感染的快速分诊提供了变革性床旁解决方案。
Resumen de: CN122609470A
本发明属于生物医药领域,具体涉及一种胸苷依赖型的鼠伤寒沙门氏菌工程菌及其组合物与应用。所述工程菌以鼠伤寒沙门氏菌VNP20009为出发菌株,经敲除胸苷酸合成酶基因thyA和插入腺苷脱氨酶编码基因,获得生长依赖外源嘧啶核苷酸、胞内表达或外膜表达腺苷脱氨酶的工程菌;胞内表达腺苷脱氨酶的工程菌为鼠伤寒沙门氏菌VNP20009‑cADD,保藏号为CGMCC No.37959;外膜表达腺苷脱氨酶的工程菌为鼠伤寒沙门氏菌VNP20009‑wADD,保藏号为CGMCC No.37956。该工程菌可肿瘤靶向定植、安全性更高,能在肿瘤局部降解腺苷、解除免疫抑制,联合放疗或免疫检查点抑制剂时可显著抑制实体瘤生长。
Resumen de: CN122603991A
The invention discloses application of a valonia tannin extract in preparation of a feed additive for removing or reducing salmonella pollution on egg shell surfaces of laying hens and a method of the valonia tannin extract. According to the method, 250-500 mg/kg of valonia tannin extract is added into basic feed of laying hens, the positive rate of salmonella on the surfaces of eggshells can be reduced to 0% from 83.3%, and thorough removal is achieved. Meanwhile, the additive has no obvious influence on escherichia coli and the total number of bacteria on the surface of the eggshell, and shows a specific removal effect on salmonella; and no adverse influence is caused on the laying rate of laying hens, egg quality, water content of excrement and other production performance indexes. The invention provides a green, efficient and specific solution for controlling egg salmonella pollution under antibiotic-free culture conditions, and has remarkable industrial application value.
Resumen de: CN122603955A
The invention discloses application of a composition in preparation of a product for relieving salmonella infection, and relates to the technical field of biology. The composition comprises the following components in parts by weight: 50-70 parts of ganoderan, 25-35 parts of jerusalem artichoke polysaccharide, 25-35 parts of lentinan, 15-25 parts of radix polygonati officinalis powder and 15-35 parts of cacumen biotae. The composition provided by the invention can be used for effectively relieving the negative damage of salmonella infection to laying hens by regulating immune inflammation balance, repairing intestinal structure damage, regulating intestinal flora structure and metabolic function in a targeted manner, remodeling cecum flora structure, enriching anti-inflammatory beneficial bacteria, inhibiting pathogenic bacteria and enhancing flora carbon water metabolic capability. The invention provides theoretical basis and data support for preventing and controlling poultry salmonellosis by using the composition as a green feed additive.
Resumen de: CN122608719A
The invention relates to the technical field of biology, in particular to an antibacterial peptide MZQ-28, a coding gene and application of the antibacterial peptide MZQ-28. The invention provides the novel antibacterial peptide MZQ-28 obtained by screening and designing based on artificial intelligence, the antibacterial peptide MZQ-28 can still maintain the antibacterial activity in a high-temperature and extreme pH environment, and has a remarkable inhibition effect on gram-negative bacteria (escherichia coli and salmonella choleraesuis) and gram-positive bacteria (staphylococcus aureus), the types of the antibacterial peptide are enriched, and the antibacterial peptide MZQ-28 can be used for preparing the antibacterial peptide. The compound is expected to be applied to preparation of products with antibacterial activity and replace antibiotics to be used for clinical treatment of fungal or bacterial infection, has potential application value in the fields of food preservation, cosmetics, biopesticide, feed additives and the like, and provides a new solution for solving the increasingly serious antibiotic drug resistance problem at present.
Resumen de: CN122612924A
0001 本发明属于致病菌检测技术领域,具体涉及一种检测沙门氏菌的SERS探针及试剂盒和检测方法。该SERS探针由金纳米双锥内核、包被金纳米双锥的普鲁士蓝壳层和偶联于探针表面的鼠伤寒沙门氏菌单克隆抗体组成,可结合噬菌体修饰的氨基化磁珠捕获技术,用于鼠伤寒沙门氏菌检测,在785 nm激发下,采集2151 cm<‑1>附近的SERS信号。结果表明,本发明的探针及检测方法,对鼠伤寒沙门氏菌的检测限为1 CFU/mL,具有良好的特异性,可避免背景干扰及其他病原菌干扰。
Resumen de: AU2026208127A1
Compositions, methods, kits, and uses are provided for detecting the presence of Salmonella, Shigella, Campylobacter, and Shigatoxigenic Escherichia coli (STEC) in samples. In some embodiments, the compositions, methods, kits, and uses comprise one or more oligonucleotides or the use of one or more oligonucleotides. ul u l
Resumen de: US20260242416A1
Antimicrobial peptides (AMPs) exhibiting broad spectrum antimicrobial activity are described. Such peptides are useful in treating or preventing infections and other conditions, and are of special interest for treating antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach leading to identification of numerous antimicrobial peptides from known genomic sequences is described.
Resumen de: US20260242806A1
0000 The invention relates to re-engineering of a natural microbial syringe for loading of effector proteins that are not naturally found as cargo of the specific syringe. The cargo, that is one or more effector protein and proteins required for packing, can be up to 300 kDa and can be proteins such as toxins, therapeutic proteins, and gene modification tools. The re-engineering of the natural syringe result in a contractile injection system that allows packing of large cargo and cargo combinations, such as toxin-chimeras. The system comprises a Conserved Virulence Cassette encoding the syringe structure and is co-expressed with a sequence encoding cargo and a signal peptide. The signal peptide comprises a packing motif that enables packing of cargo into the syringe. The contractile injection system can be used for agricultural purposes as well as for medicinal purposes.
Resumen de: US20260240985A1
0000 The present invention relates to a non-viable bacterium cell wherein an immunogenic polypeptide fused to an auto-transporter comprising transmembrane linker and a trans-porter domain is displayed on the surface of the cell, and to a preparation comprising such non-viable cells. The preparation is useful as an oral vaccine.
Resumen de: US20260243764A1
Described herein is a biosensor for detecting the presence of a target molecule in a sample. The biosensor comprises: a polymeric hydrogel; a colorimetric indicator entrapped in the polymeric hydrogel; and an oligonucleotide that crosslinks the polymeric hydrogel, wherein the oligonucleotide is separated in the presence of the target molecule, thereby releasing the colorimetric indicator from the hydrogel.
Resumen de: WO2025080776A2
Aspects of the invention described herein relate to a vaccine composition comprising at an antigenic polysaccharide and an immunomodulatory amount of a sialic acid binding moiety, wherein the sialic acid binding moiety comprises sialic acid binding domain (SBD) which is not fused to an antigenic polypeptide.
Resumen de: WO2022032100A2
The presently disclosed subject matter provides compositions, kits, and methods comprising imaging agents that can detect Programmed Cell Death Ligand 1 (PD-L1). The presently disclosed imaging agents can be used to detect diseases and disorders, such as cancer, infection, and inflammation, in a subject.
Resumen de: CN122588122A
The invention relates to a method for carrying out cross-genus conjugational transfer from salmonella pSLT plasmids to escherichia coli, and belongs to the technical field of microbial genetic engineering and horizontal gene transfer. According to the method, recombinant pSLT plasmids containing selection markers are constructed, and the problem that the pSLT plasmids are difficult to identify is solved; by researching conjugation transfer conditions, a trans-genus conjugation transfer method of the pSLT plasmid from salmonella to escherichia coli is established, and the host limitation is broken through; a dual verification system for successful transfer of recombinant plasmids: phenotype verification and molecular verification is established, so that the accuracy of a transfer result is ensured.
Resumen de: CN122588018A
The invention belongs to the technical field of biological prevention and control and food safety, and discloses a bacteriophage Yrd1 capable of cracking salmonella pullorum, a biological preparation containing the bacteriophage Yrd1 and application of the bacteriophage Yrd1. The bacteriophage Yrd1 is obtained by taking salmonella pullorum as host bacteria through separation, is named as Salmonella pullorum Yrd1, is preserved in the China Center for Type Culture Collection on April 22, 2026, has the preservation number of CCTCC NO: M 2026766, and has good lysis activity and biological stability. The biological preparation containing the bacteriophage can be prepared into a liquid preparation, a freeze-dried powder preparation, a spray preparation, a preparation for drinking water addition, a preparation for feed addition or a food surface treatment preparation, is used for biological prevention and control of salmonella pullorum, and is especially suitable for inhibiting or reducing salmonella pullorum pollution in chicken juice, chicken and other chicken related matrixes.
Resumen de: CN122598171A
The invention provides a method and a system for rapidly detecting salmonella in food based on machine learning, and relates to the field of computer vision. The method specifically comprises the following steps: acquiring a food microscopic image, and constructing a microscopic input image; a microscopic input image is input into a self-adaptive preprocessing module, and preprocessing features are obtained after background separation, contrast and edge enhancement and denoising; extracting prior information of the preprocessing features through candidate connected domains, adding the prior information with the preprocessing features, performing coding, and performing alignment, multi-branch convolution and enhancement function joint analysis to obtain multi-scale features; constructing a thallus-impurity decoupling discrimination module to realize differential decoupling discrimination of the target and the impurities to obtain discrimination characteristics; and constructing an evidence accumulation module to jointly count multi-scale features, and performing threshold segmentation after multi-evidence fusion enhancement to output a result. According to the method, complex food matrix background interference can be effectively inhibited, the morphological expression of salmonella is enhanced, and the accuracy and stability of detection in a complex scene are improved.
Nº publicación: CN122582271A 18/08/2026
Solicitante:
无锡市南京大学锡山应用生物技术研究所
Resumen de: CN122582271A
本发明公开一种基于细菌的肿瘤原位疫苗,包括灭活细菌和腺苷脱氨酶,所述灭活细菌为大肠杆菌(Escherichia coli) Nissle 1917或减毒鼠伤寒沙门氏菌(VNP 20009)中的任意一种或两种。本发明的肿瘤原位疫苗对宿主脏器无明显毒副作用,具有良好的安全性,生产制备工艺简单、成本低;可通过瘤内注射方式刺激机体先天性和适应性免疫系统,增强抗肿瘤免疫,抑制肿瘤细胞生长,有效预防肿瘤的发生发展和复发转移。